CClinicalTrials.gg
RecruitingNCT03267459PREDIRUpdated Jan 5, 2026

Can Pretreatment MRI be Used to Predict Intra-arterial Chemotherapy Response in Retinoblastoma?

An observational study in Retinoblastoma, sponsored by Fondation Ophtalmologique Adolphe de Rothschild. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by Fondation Ophtalmologique Adolphe de Rothschild · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
60
Sex
All
01

Study summary

Retinoblastoma is the most frequent intraocular tumor in children and represents 6% of all pediatric cancers before the age of 5 years-old. The outcome is now excellent with 95 to 97% of 5-years survival rate. Conservative treatments are being more and more used, and intra arterial chemotherapy is one of the adjuvant treatments proposed to the children. The treatment is efficient in most cases, but a small proportion of children will have an early progression after treatment. MRI is used for the diagnosis of retinoblastoma. We aim to find prognostic factors using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for early identification of children response to intra arterial chemotherapy.

02

Conditions studied

  • Retinoblastoma

Browse trials for

03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patient with retinoblastoma, undergoing intra arterial chemotherapy

Inclusion criteria

  • grade B to D retinoblastoma
  • prescription of intra arterial chemotherapy

Exclusion criteria

Exclusion Criteria:

  • none
04

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Interventions

  • DeviceDynamic contrast-enhanced MRI

    Dynamic contrast-enhanced perfusion sequences added to MRI examination performed at the beginning of intra arterial chemotherapy.

05

What researchers measure

Primary outcomes

  1. response to chemotherapy

    Persistence of ocular scarring (= favorable outcome)18 months after the end of the treatment by intra-arterial chemotherapy.

    Time frame: 18 months

06

Study locations

1 of 1 sites recruiting
  • Fondation A De Rothschild
    Paris, 75019, France
    Recruiting
07

Registry details

Key details

Study ID
NCT03267459
Lead sponsor
Fondation Ophtalmologique Adolphe de Rothschild
Responsible party
Sponsor
First posted
Aug 30, 2017
Start date
Jan 11, 2018
Primary completion
Jan 2028 (estimated)
Completion
Jul 2030 (estimated)
Last update
Jan 5, 2026

Study contacts

Laurence Salomon, MD PhD
Contact
lsalomon@for.paris
0148036431
Augustin Lecler, MD
Contact
alecler@for.paris
Augustin Lecler, MD
principal investigator · Fondation OPH A de Rothschild

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion